Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2015
|
Clark Golestani EVP & Chief Info Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,291
+18.26%
|
-
|
|
May 02
2015
|
Weir Mirian M Graddick Exe V-P, HR |
SELL
Payment of exercise price or tax liability
|
Direct |
4,488
-3.86%
|
$264,792
$59.86 P/Share
|
|
May 02
2015
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Exercise of conversion of derivative security
|
Direct |
8,654
+6.92%
|
-
|
|
May 02
2015
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,755
-11.6%
|
$103,545
$59.86 P/Share
|
|
May 02
2015
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
4,709
+23.74%
|
-
|
|
May 02
2015
|
Michael Rosenblatt Exec V-P & Chief Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,980
-5.73%
|
$116,820
$59.86 P/Share
|
|
May 02
2015
|
Michael Rosenblatt Exec V-P & Chief Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,818
+9.96%
|
-
|
|
May 02
2015
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
8,709
-45.02%
|
$513,831
$59.86 P/Share
|
|
May 02
2015
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
19,343
+50.0%
|
-
|
|
Apr 29
2015
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
SELL
Open market or private sale
|
Direct |
156,902
-30.2%
|
$9,257,218
$59.79 P/Share
|
|
Apr 29
2015
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
156,902
+21.65%
|
$5,805,374
$37.93 P/Share
|
|
Apr 29
2015
|
Michael J Holston EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
95,624
-70.51%
|
$5,641,816
$59.84 P/Share
|
|
Apr 29
2015
|
Michael J Holston EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
135,624
+31.83%
|
$5,967,456
$44.63 P/Share
|
|
Apr 13
2015
|
William B Harrison Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+30.49%
|
$165,000
$33.83 P/Share
|
|
Feb 23
2015
|
Adele D Ambrose Sr.V-P & Chief Comuns Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,462
+12.75%
|
$142,796
$58.3 P/Share
|
|
Feb 23
2015
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
84,836
+16.22%
|
$4,920,488
$58.3 P/Share
|
|
Feb 23
2015
|
Willie A Deese Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
8,762
+7.08%
|
$508,196
$58.3 P/Share
|
|
Feb 23
2015
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
6,649
+41.43%
|
$385,642
$58.3 P/Share
|
|
Feb 23
2015
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,736
+11.35%
|
$158,688
$58.3 P/Share
|
|
Feb 23
2015
|
Clark Golestani EVP & Chief Info Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,466
+12.81%
|
$85,028
$58.3 P/Share
|
|
Feb 23
2015
|
Weir Mirian M Graddick Exe V-P, HR |
BUY
Grant, award, or other acquisition
|
Direct |
11,190
+9.48%
|
$649,020
$58.3 P/Share
|
|
Feb 23
2015
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
14,282
+9.04%
|
$828,356
$58.3 P/Share
|
|
Feb 23
2015
|
Michael Rosenblatt Exec V-P & Chief Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,001
+14.1%
|
$290,058
$58.3 P/Share
|
|
Feb 23
2015
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
22,198
+50.0%
|
$1,287,484
$58.3 P/Share
|
|
Feb 18
2015
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
5,164
-1.44%
|
$299,512
$58.67 P/Share
|
|
Feb 18
2015
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
7,082
+1.94%
|
$219,542
$31.84 P/Share
|
|
Feb 11
2015
|
Willie A Deese Exe V-P & Pres. MMD |
SELL
Open market or private sale
|
Direct |
135,864
-56.12%
|
$7,880,112
$58.56 P/Share
|
|
Feb 11
2015
|
Willie A Deese Exe V-P & Pres. MMD |
BUY
Exercise of conversion of derivative security
|
Direct |
135,864
+18.78%
|
$5,434,560
$40.66 P/Share
|
|
Feb 09
2015
|
Wendell Peter C Director |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$290,000
$58.76 P/Share
|
|
Feb 09
2015
|
Wendell Peter C Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$165,000
$33.83 P/Share
|
|
Jan 15
2015
|
Adam H Schechter EVP & Pres-Global Human Health |
SELL
Open market or private sale
|
Direct |
74,200
-100.0%
|
$4,600,400
$62.48 P/Share
|
|
Jan 15
2015
|
Adam H Schechter EVP & Pres-Global Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
74,200
+26.01%
|
$2,745,400
$37.92 P/Share
|
|
Jan 09
2015
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
8,840
-2.45%
|
$548,080
$62.47 P/Share
|
|
Jan 09
2015
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
12,874
+1.76%
|
$424,842
$33.47 P/Share
|
|
Dec 10
2014
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
9,846
-2.76%
|
$590,760
$60.0 P/Share
|
|
Dec 10
2014
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
12,874
+1.78%
|
$424,842
$33.47 P/Share
|
|
Dec 08
2014
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
SELL
Open market or private sale
|
Direct |
50,000
-28.02%
|
$3,100,000
$62.0 P/Share
|
|
Dec 08
2014
|
Bruce N Kuhlik Exe V-P & Gen Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+21.89%
|
$2,550,000
$51.02 P/Share
|
|
Nov 26
2014
|
Rochelle B Lazarus Director |
SELL
Open market or private sale
|
Direct |
10,000
-68.52%
|
$590,000
$59.63 P/Share
|
|
Nov 26
2014
|
Rochelle B Lazarus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+29.89%
|
$340,000
$34.14 P/Share
|
|
Nov 24
2014
|
Wendell P Weeks Director |
SELL
Open market or private sale
|
Direct |
5,000
-66.13%
|
$295,000
$59.13 P/Share
|
|
Nov 24
2014
|
Wendell P Weeks Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.51%
|
$165,000
$33.83 P/Share
|
|
Nov 10
2014
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
10,000
-2.82%
|
$570,000
$57.98 P/Share
|
|
Nov 10
2014
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
12,875
+1.79%
|
$424,875
$33.47 P/Share
|
|
Nov 02
2014
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Payment of exercise price or tax liability
|
Direct |
1,635
-37.27%
|
$93,195
$57.94 P/Share
|
|
Nov 02
2014
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+50.0%
|
-
|
|
Oct 10
2014
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
9,895
-2.82%
|
$583,805
$59.73 P/Share
|
|
Oct 10
2014
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
12,875
+1.81%
|
$424,875
$33.47 P/Share
|
|
Sep 10
2014
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
9,814
-2.82%
|
$588,840
$60.48 P/Share
|
|
Sep 10
2014
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
12,875
+1.82%
|
$424,875
$33.47 P/Share
|